Published in
American Association for the Advancement of Science, Science Translational Medicine, 394(9), 2017
DOI: 10.1126/scitranslmed.aah6144
Links
- ORCID
- ORCID
- American Association for the Advancement of Science
- [europepmc.org] | PDF
- [europepmc.org] | PDF
- [eprints.bbk.ac.uk] | PDF
Tools
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
Journal article published in 2017 by
Dennis Plenker 
,
Maximilian Riedel ,
Johannes Brägelmann ,
Marcel A. Dammert,
Rakhee Chauhan,
Phillip P. Knowles,
Carina Lorenz,
Marina Keul ,
Mike Bührmann,
Oliver Pagel ,
Verena Tischler,
Andreas H. Scheel ,
Daniel Schütte,
Yanrui Song ,
Justina Stark
and other authors.
,
Maximilian Riedel ,
Johannes Brägelmann ,
Marcel A. Dammert,
Rakhee Chauhan,
Phillip P. Knowles,
Carina Lorenz,
Marina Keul ,
Mike Bührmann,
Oliver Pagel ,
Verena Tischler,
Andreas H. Scheel ,
Daniel Schütte,
Yanrui Song ,
Justina Stark
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
An examination of the activity profiles of RET inhibitors suggests potential treatment forRET-rearranged cancers.